Kazia licencia los derechos globales de EVT801, un nuevo inhibidor clinic de VEGFR3, de Evotec SE

By In The News
April 19, 2021 in The Headlines

Recommended Posts

In The News

Posted April 19, 2021

- Share

Posted April 19, 2021

SIDNEY, 19 de abril de 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), una empresa de desarrollo de fármacos centrada en la oncología, se complace en anunciar que ha entrado en un acuerdo mundial de licencias exclusivas y un acuerdo de servicios maestros con...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219854
2. Jaydee
  16745
3. Kip Powick
  12210
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.1k
- Total Posts
  
  558.6k

Sign In

Kazia licencia los derechos globales de EVT801, un nuevo inhibidor clinic de VEGFR3, de Evotec SE

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support